WILMINGTON, Del.

威尔明顿，德拉瓦州

,

，

March 20, 2026

2026年3月20日

/PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced that it has raised $787 million in financing rounds. The investment included participation by a group of leading global investors, including Dimension Capital, DST Global, INCE Capital, Luminous Ventures, Miracle Capital, Sanofi, and Biotech Development Fund (created by Hillhouse and Pfizer), alongside other existing and new technology and healthcare-focused investors..

/PRNewswire/ -- Earendil Labs，一家由人工智能驱动的生物技术公司，致力于推进下一代生物制品的发展，今天宣布已在融资轮中筹集了7.87亿美元。此次投资包括一组全球领先投资者的参与，其中包括 Dimension Capital、DST Global、INCE Capital、Luminous Ventures、Miracle Capital、Sanofi 和 Biotech Development Fund（由高瓴和辉瑞创立），以及其他现有的和新加入的技术与医疗保健领域专注的投资者。

The funding will accelerate Earendil Labs' AI-driven R&D platform, expand its interdisciplinary teams, and advance a growing pipeline of antibody and biologics programs, with the goal of delivering first-in-class and best-in-class therapies for patients with serious diseases.

这笔资金将加速Earendil Labs的AI驱动研发平台的发展，扩大其跨学科团队，并推进越来越多的抗体和生物制品项目，目标是为患有严重疾病的患者提供首创和同类最佳的治疗方法。

'AI is at the core of everything we do — not as a research tool, but as a production engine for real therapeutic programs,' said Jian Peng, PhD, Founder and CEO of Earendil Labs. 'This financing allows us to operate at a fundamentally different scale, advancing multiple programs toward the clinic while building an R&D organization designed for long-term impact.'.

“人工智能是我们所做的一切的核心——它不是一种研究工具，而是一个为真正治疗计划提供动力的生产引擎，”Earendil Labs创始人兼首席执行官彭健博士说道。“这笔融资使我们能够在完全不同的规模上运作，在推动多个项目走向临床的同时，建立一个为长期影响而设计的研发组织。”

Earendil Labs integrates artificial intelligence across the full life cycle of biologics R&D, enabling the systematic generation and progression of differentiated therapeutic programs. The company's AI-native platform has produced more than 40 programs, including HXN-1001, a half-life extended anti-TL1A antibody which is ready for Phase 2 clinical development, together with multiple IND submissions planned in 2026 and 2027..

Earendil Labs在生物制品研发的整个生命周期中整合了人工智能，从而能够系统地生成和推进差异化的治疗项目。该公司原生的人工智能平台已经产出了40多个项目，其中包括HXN-1001——一种半衰期延长的抗TL1A抗体，已准备好进入二期临床开发——并且计划在2026年和2027年提交多项IND申请。

'Our focus is ultimately on patients suffering from diseases that still lack effective treatment options,' said Zhenping Zhu, MD, PhD, Co-Founder, President and Co-CEO of Earendil Labs. 'This funding greatly strengthens our ability to translate AI-enabled innovation into potentially transformative medicines and provides opportunities to partner with global leaders to accelerate our research and development programs worldwide.

“我们的关注点最终是那些仍然缺乏有效治疗选择的疾病患者，”Earendil Labs联合创始人、总裁兼联席首席执行官朱振平博士表示。“这笔资金极大地增强了我们将人工智能驱动的创新转化为潜在变革性药物的能力，并提供了与全球领导者合作的机会，以加速我们在全球范围内的研发计划。”

'.

。

The platform's productivity and R&D execution are further validated through strategic collaborations with Sanofi. In 2025, Earendil Labs announced a worldwide exclusive license agreement with Sanofi for next-generation bispecific antibodies for autoimmune and inflammatory bowel diseases, covering HXN-1002 and HXN-1003.

通过与赛诺菲的战略合作，进一步验证了该平台的生产力和研发执行力。2025年，Earendil Labs宣布与赛诺菲达成了一项全球独家许可协议，涉及用于自身免疫和炎症性肠病的下一代双特异性抗体，涵盖HXN-1002和HXN-1003。

More recently, Earendil Labs and Sanofi entered a broader strategic collaboration to apply its AI-driven discovery platform to multiple autoimmune and inflammatory disease programs..

最近，Earendil Labs和赛诺菲达成了一项更广泛的战略合作，将其人工智能驱动的发现平台应用于多个自身免疫和炎症性疾病项目。

'Earendil Labs stands out for its ability to translate AI innovation into real, scalable R&D execution,' said Zavain Dar, Founding Managing Partner at Dimension Capital. 'The team has shown that AI can consistently generate high-quality biologics programs and advance them toward the clinic. We are excited to support Earendil Labs as it builds a new paradigm for biologics discovery and development.'.

“Earendil Labs 凭借其将人工智能创新转化为实际且可扩展的研发执行能力而脱颖而出，”Dimension Capital 的创始管理合伙人 Zavain Dar 表示。“该团队已经证明，人工智能可以持续生成高质量的生物制品项目并推动它们走向临床。我们非常高兴支持 Earendil Labs 构建生物制品发现与开发的新范式。”

With this funding, Earendil Labs plans to scale its AI-driven research and development across biologics discovery and development while expanding its scientific, engineering, and translational teams to support pipeline growth. The capital will also advance multiple internal programs toward clinical milestones and deepen strategic partnerships to accelerate the delivery of innovative biologics to patients globally..

通过这笔资金，Earendil Labs计划扩大其在生物制品发现和开发领域的人工智能驱动研发规模，同时扩展其科学、工程和转化团队以支持管线增长。这笔资金还将推动多个内部项目迈向临床里程碑，并深化战略合作伙伴关系，以加速将创新生物制品带给全球患者。

About Earendil Labs

关于Earendil Labs

Earendil Labs is an AI-powered biotechnology company advancing next-generation biologics for patients with autoimmune diseases, cancer, and other areas of significant unmet medical need. By integrating artificial intelligence across the full R&D

Earendil Labs是一家人工智能驱动的生物技术公司，致力于为自身免疫疾病、癌症和其他具有重大未满足医疗需求的领域开发下一代生物制剂。通过在研发全过程整合人工智能，

life cycle

生命周期

, Earendil Labs and its affiliate Helixon Therapeutics have been building a scalable engine to systematically generate and advance high-quality therapeutic programs.

Earendil Labs及其附属公司Helixon Therapeutics一直在构建一个可扩展的引擎，以系统地生成和推进高质量的治疗项目。

The company's AI-native approach enables efficient creation, optimization, and progression of protein-based biologics with the potential to be first-in-class and best-in-class, translating computational innovation into real clinical and patient impact. Through a combination of internal pipeline development and strategic partnerships, Earendil Labs aims to deliver transformative medicines to patients worldwide..

公司的人工智能原生方法能够高效创建、优化和推进基于蛋白质的生物制剂，有潜力成为同类最佳，将计算创新转化为真正的临床和患者影响。通过内部管线开发与战略合作伙伴关系的结合，Earendil Labs 旨在为全球患者提供变革性药物。

SOURCE Earendil Labs

来源：Earendil Labs

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示